Nektar Therapeutics
NASDAQ:NKTR
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.42
1.83
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Nektar Therapeutics
Nektar Therapeutics
Non-Reccuring Items
Nektar Therapeutics
Non-Reccuring Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Non-Reccuring Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nektar Therapeutics
NASDAQ:NKTR
|
Non-Reccuring Items
-$17.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Non-Reccuring Items
-$7.3B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-35%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Non-Reccuring Items
-$16.8B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-151%
|
CAGR 10-Years
-37%
|
|
|
Pfizer Inc
NYSE:PFE
|
Non-Reccuring Items
-$10.1B
|
CAGR 3-Years
-50%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-15%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Non-Reccuring Items
-$8.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
-13%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Non-Reccuring Items
-$4.3B
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-33%
|
|
Nektar Therapeutics
Glance View
Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. The company is headquartered in San Francisco, California and currently employs 740 full-time employees. The firm's research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, it is studying several immuno-oncology (I-O) drug candidates, including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In autoimmune disorders, its IL-2 T-regulatory cell stimulator NKTR-358 is being clinically studied in systemic lupus erythematosus, ulcerative colitis, psoriasis and atopic dermatitis. Its programs in virology area include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. (Gilead) to test the combination of NKTR-255.
See Also
What is Nektar Therapeutics's Non-Reccuring Items?
Non-Reccuring Items
-17.2m
USD
Based on the financial report for Sep 30, 2024, Nektar Therapeutics's Non-Reccuring Items amounts to -17.2m USD.
What is Nektar Therapeutics's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 1Y
88%
Over the last year, the Non-Reccuring Items growth was 88%.
You don't have any saved screeners yet
